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Pompe disease (PD) is a rare metabolic myopathy. It is 
caused by the deficiency of the lysosomal enzyme acid alpha 
glucosidase (GAA), with a consequent generalized storage of 
glycogen, particularly in the heart, skeletal muscle and liver.
It has been reported an overall incidence of 1 in 40.000 live 
birth, with a different frequency in different races. The infantile 
form has an incidence of 1 in 138.000 among Caucasians. 
The disease is characterized by phenotypic and biochemi-
cal heterogeneity with variable age of onset, from infantile to 
adult age and varying levels of residual enzyme activity, which 
are inversely related to the severity of clinical manifestations. 
The disease is also characterized by wide genetic heterogene-
ity, and more than 200 different mutations of different severity 
have been described with variable genotype-phenotype corre-
lations. 
In infantile Pompe disease the most affected muscles are 
the heart, respiratory and proximal skeletal muscles of the limbs. 
The clinical onset may occur in the first weeks/months of life. 
Patients with the classic infantile phenotype may present with 
severe cardiomegaly, hypertrophic cardiomyopathy and heart 
failure, which are associated with generalized muscle weak-
ness and delay in motor development. Pulmonary involvement 
is characterized by recurrent respiratory infections and respi-
ratory failure. Malnutrition, poor growth, feeding difficulties, 
macroglossia  and  hepatomegaly  are  also  evident.  Biochemi-
cal investigations reveal hypertransaminasemia with increased 
creatine phosphokinase (CPK). 
Studies of the natural history show that clinical manifesta-
tions are progressive, with poor prognosis and early exitus due 
to cardiorespiratory complications. Data from the International 
Pompe disease Registry (1) show that the most frequent muscle 
symptoms are hypotonia, inability to deambulation, weakness 
of proximal limbs muscles. Pneumonia and respiratory distress 
are commonly reported in various age groups, while heart fail-
ure is prevalent in younger patients. 
In fact, severe heart involvement is typical of the classic 
infantile form and it can be detected by simple and cheap di-
agnostic investigations as chest x-ray and ECG that guide the 
diagnostic suspicion. Chest x-ray shows severe cardiomegaly 
and ECG reveals suggestive abnormalities like short PR, large 
QRS voltage, repolarization abnormalities and signs of left ven-
tricular hypertrophy. Echocardiogram shows hypertrophic car-
diomyopathy.
Cardiac manifestations are absent or very mild in non clas-
sic infantile and juvenile forms. Juvenile patients may present 
with progressive muscle weakness, myalgias, scapular winging 
and spine stiffness in combination with recurrent respiratory in-
fections, respiratory failure, nocturnal apneas and complications 
such as scoliosis or feeding problems. 
Difficulties in differential diagnosis may determine a vari-
able diagnostic delay. A simple diagnostic algoritm in infantile 
forms has been proposed by national and international guide-
lines (2, 3). GAA enzymatic assay should be firstly performed 
in patients showing hypertrophic cardiomyopathy in combina-
tion  with  generalized  hypotonia,  hypertransaminasemia  and 
incresased CPK. Muscle biopsy may show glycogen storage, 
but its usefulness in the diagnostic approach is controversial in 
infantile patients.
GAA enzymatic assay should be performed in lymphocytes, 
fibroblasts or muscle biopsy. Recently innovative methods, such 
as measurement of GAA activity in dried blood spots by tandem 
mass spectroscopy, can be used to investigate suspected patients 
and in newborns screening programs. Moreover a tetra glucose 
oligomer designated as Glc4 has been shown to be elevated in 
both urine and plasma of PD patients and it could be used as a 
non-invasive marker for diagnosis and monitoring of therapeu-
tic response. 
Diagnosis of PD is confirmed by molecular analysis of 
GAA  gene  and  identification  of  causative  mutations  is  also 
helpful for familial screening and prenatal diagnosis.
Although  Pompe  disease  is  a  hereditary  myopathy  it  is 
characterized  by  multisystem  involvement;  management  of 
patients  is  multidisciplinary,  involving  different  specialists. 
In classic infantile PD patients cardiac involvement is serious 
and cardiac supportive treatment is often needed. Respiratory 
involvement  is  due  to  concomitant  factors  as  muscle  weak-
ness, reduced thoracic compliance, poor cough and recurrent 
infections. Respiratory support is one of the most critical forms 
of management for Pompe disease, as most patients experience 
some form of respiratory compromise, and respiratory failure is 
the most common cause of premature death. Other interventions 
may include special forms of physical therapy to strengthen 
weakened respiratory muscles, as well as aggressive manage-
ment of infections. Physical therapy has an important role to 
prevent contractures and deformity. As growth failure and feed-
ing difficulties are common in children with PD, nutritional 
intervention is required. Recently videofluoroscopic study of 
swallowing  demonstrated  that  pediatric  PD  patients  show 
oropharyngeal dysphagia with airway invasion and poor cough 
reflex. Videofluoroscopic assessment of dysphagia should be 
recommended in PD pediatric patients to establish the need for 
supportive treatment. Similarly hearing loss is now increasingly 
recognized in classic infantile patients and periodical hearing 
assessment should be performed. 
In conclusion multidisciplinary follow-up, coordinated by 
a metabolic pediatrician or a pediatric neurologist, is needed in 
PD patients for early identification and supportive treatment of 
multi-organ complications. 
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